Janux Therapeutics annual capital expenditures (capex)
2020
2021
2022
2023
2024
2025
Janux Therapeutics Capital Expenditures (CapEx) Growth & History (JANX)
Janux Therapeutics's capital expenditures (capex) was $1.0M for fiscal 2025.
View full Janux Therapeutics company overviewJanux Therapeutics annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.0M | $684,000 | +190.53% |
| 2024 | 2024-12-31 | $359,000 | −$1.5M | −80.59% |
| 2023 | 2023-12-31 | $1.9M | −$4.6M | −71.30% |
| 2022 | 2022-12-31 | $6.4M | $5.0M | +334.89% |
| 2021 | 2021-12-31 | $1.5M | $1.5M | — |
| 2020 | 2020-12-31 | $0 | — | — |
Janux Therapeutics quarterly capital expenditures (capex)
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $202,000 | −$271,000 | −57.29% |
| Q1 2026 | 2026-03-31 | $273,000 | −$98,000 | −26.42% |
| Q4 2025 | 2025-12-31 | $106,000 | $64,000 | +152.38% |
| Q3 2025 | 2025-09-30 | $93,000 | $68,000 | +272.00% |
| Q2 2025 | 2025-06-30 | $473,000 | $378,000 | +397.89% |
| Q1 2025 | 2025-03-31 | $371,000 | $174,000 | +88.32% |
| Q4 2024 | 2024-12-31 | $42,000 | −$473,000 | −91.84% |
| Q3 2024 | 2024-09-30 | $25,000 | −$445,000 | −94.68% |
| Q2 2024 | 2024-06-30 | $95,000 | −$485,000 | −83.62% |
| Q1 2024 | 2024-03-31 | $197,000 | −$88,000 | −30.88% |
| Q4 2023 | 2023-12-31 | $515,000 | −$1.5M | −74.95% |
| Q3 2023 | 2023-09-30 | $470,000 | −$2.0M | −81.35% |
| Q2 2023 | 2023-06-30 | $580,000 | −$318,000 | −35.41% |
| Q1 2023 | 2023-03-31 | $285,000 | −$686,000 | −70.65% |
| Q4 2022 | 2022-12-31 | $2.1M | $883,000 | +75.28% |
| Q3 2022 | 2022-09-30 | $2.5M | $2.4M | +3172.73% |
| Q2 2022 | 2022-06-30 | $898,000 | $819,000 | +1036.71% |
| Q1 2022 | 2022-03-31 | $971,000 | $818,000 | +534.64% |
| Q4 2021 | 2021-12-31 | $1.2M | — | — |
| Q3 2021 | 2021-09-30 | $77,000 | $77,000 | — |
| Q2 2021 | 2021-06-30 | $79,000 | — | — |
| Q1 2021 | 2021-03-31 | $153,000 | — | — |
| Q3 2020 | 2020-09-30 | $0 | — | — |
Janux Therapeutics capital expenditures (capex) trends
Over the last five fiscal years, Janux Therapeutics's capital expenditures (capex) increased from $0 to $1.0M, a change of $1.0M. The latest reported quarter, Q2 2026, shows $202,000.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Janux Therapeutics source filings ↗